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ABSTRACT
Bifidobacteria are categorized as health-promoting microorganisms (probiotics) in the gastrointestinal tracts of  humans 
and animals. Antibiotic susceptibility is a key criterion for probiotic agent selection. Good survival of  probiotics 
during storage at selected storage temperature(s) is highly desirable. Bifidobacteria isolated from human and chicken 
were thus characterized phenotypically by their ability to produce fructose-6-phosphoketolase enzyme. Eight selected 
isolates were then characterized on molecular basis employing genus-specific and species-specific 16S rRNA gene 
primers, and their antibiotic susceptibilities were also evaluated. Isolates were confirmed to be strains of  B. catenulatum 
(4) and B. adolescentis (4). Studied strains were resistant to streptomycin, gentamycin, cloxacillin and cotrimoxazole 
but susceptible to chloramphenicol, augmentin, amoxicillin and erythromycin. Three strains (B. catenulatum HM2, B. 
catenulatum HM3 and B. catenulatum HM5) showed atypical tetracycline resistance. B. catenulatum HM2, B. adolescentis 
CH2 and B. adolescentis CH3 showed significant reduction in counts (p < 0.05) and survived in adequate amount in 
yoghurt stored at 4˚C and -18˚C for 4 weeks. In addition to presenting acceptable antibiotic susceptibility profile and 
exhibiting good survival in stored yoghurt, the bifidobacteria isolates inhibited Staphylococcus aureus ATCC 25925 and 
Escherichia coli ATCC 25922 in-vitro and demonstrated potential for application as probiotic agents for human and 
agricultural purposes.
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Introduction
Bifidobacterium species are reported to present 
evidence of  distinct immunomodulatory effect 
in-vitro and in-vivo (Chenoll et al., 2011; Fujiwara 
et al., 2004; Isolauri et al., 2000; Reid et al., 2003). 
Poupard et al. (1973) concluded, after elaborate 
revision of  investigation reports on bifidobacteria 
and the better health of  breast-fed infants, that 
bifidobacteria aid in better nutrition of  infants and, 
thus, indirectly contributes to greater resistance 
to infection. The popularity of  bifidobacteria in 
many commercial probiotic products can be traced 
to their beneficial effects such as antagonism 
against other microorganisms, anti-mutagenic and 
anti-carcinogenic properties, anti-inflammatory, 
cholesterol reduction activities, and general well-
being of  host (Pereira and Gibson, 2002; Wagner et 
al., 1997; Xiao et al., 2006a; Xiao et al., 2006b).
The increasing application of  viable microorganisms 
also goes with the increasing probability of  negative 
health impact through the use of  wrong probiotic 
agents. Classical methods of  identification and 
classification of  microorganisms usually involve 
cultivation on selective media, colony analysis, 
and microscopic examination, followed by 
biochemical tests. This protocol is known to be 
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prone to error, variability, and it is time consuming. 
Other taxonomic tools that are conventionally 
used include bacteriophage typing, serotyping 
and antibiotic susceptibility patterns. These also 
have their peculiar limitations. In bifidobacteria 
taxonomic work, the demonstration of  the enzyme 
fructose-6-phosphate phosphoketolase in cell-
free extract of  bifidobacteria has been used as 
confirmation for Bifidobacterium species (Kimura et 
al., 1997). Currently, molecular techniques are being 
favoured widely for confirmatory identification of  
microorganisms including bifidobacteria (Biavati et 
al., 1982; Duranti et al., 2013; Matsuki et al., 2002; 
Wendy and Lynne, 1998). One of  such techniques 
is the use of  genus-specific and species-specific 
16S rRNA gene primers in bacteria identification 
(Fujimoto and Watanabe, 2013; Matsuki et al., 2002; 
Wendy and Lynne, 1998).
The issue of  safety (Donohue and Salminen, 1996; 
Ishibashi and Yamazaki, 2001) brings to fore the 
need for accurate identification of  probiotics, 
usually accomplished through molecular methods 
(Langendijk et al., 1995; Matsuki et al., 1999; 
Satokari et al., 2001; Scardovi and Crociani, 1974; 
Ventura et al., 2001). A more specific safety concern 
is the issue of  antibiotic resistance transfer from 
probiotics to other intestinal microbes. Minimizing 
this possibility in probiotic product development 
is a major prerequisite. The issue of  safety of  
probiotics, like that of  other internally consumed 
products, continues to receive emphasis. For 
instance while possession of  antibiotic resistance 
is sought after in probiotic combined therapy with 
antibiotics, the fear of  resistance-gene transfer to 
other intestinal microorganisms appears real. The 
existence and activities of  mobile DNAs such 
as transposons, retrotransposons, plasmids and 
viruses in microbes have been reported (Climo 
et al., 1996; Grohmann et al., 2003). So far no 
mobile DNA on antibiotic resistance has been 
confirmed in bifidobacteria to our knowledge. 
Only atypical tetracycline resistance gene tet (W) 
have been observed (Masco et al., 2006; Moubareck 
et al., 2005). Available reviews and research reports 
severally concluded that bifidobacteria are safe for 
human and animal use (Donohue and Salminen, 
1996; Ishibashi and Yamazaki, 2001; Masco et al., 
2006; Moubareck et al., 2005). 
Probiotics are often included in fermented milks, 
infant formulas, cheese, ice cream and related 
products to improve their health beneficial 
properties. The value and benefits of  bifidobacteria 
are yet to be enjoyed in sub-Saharan African 
countries, including Nigeria. The focus of  this 
study was to isolate, characterize, and evaluate 
Bifidobacterium species that can be used as probiotic 
agents in humans and animal agricultural practices.
Materials and Methods
Bacteria culture
The cultures used in this study were isolated from 
faecal samples of  adult human and intestinal 
content of  chicken using the Bifidobacterium medium 
of  Nebra and Blanch (1999). The Oxoid anaerobic 
system (Oxoid jar with Oxoid AnaeroGen: O2 
below 1%, CO2 9% – 13%) was used throughout 
in this project when anaerobic incubation was 
required. Isolates were stored in sterile Oxoid MRS 
broth with 20% glycerol at -20°C when long period 
of  storage was required (Monaghan et al., 1999).
Phenotypic identification
Isolated gram positive catalase negative rods were 
further identified phenotypically by demonstration 
of  fructose-6-phosphate phosphoketolase. This 
test was performed based on specified method 
(Zinedine and Faid, 2007). 
DNA isolation
DNA extraction was performed using the method 
of  Alander et al. (1999) with modification. Cells 
were harvested from 24 h MRS broth culture (1.5 
ml) by centrifuging at 13,000 rpm for 15 min. 
Cells were washed twice in normal saline by 
centrifuging (Eppendorf  5415R refrigerated 
centrifuge, Eppendorf, Germany), 200 µl of  solution 
containing 10 mm Tris-HCl (pH 8) and 2.5 mg/ml 
of  lysozyme was added, and content subsequently 
vortexed. Tubes were incubated at 37˚C for 2h, 400 
µl of  lysis buffer (50mM Tris-HCl, 100mM EDTA, 
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1% SDS, pH 8) and 1mg/ml of  proteinase k was 
added. Tube content was mixed and incubated in a 
water bath at 50˚C for 1h. This was followed with 
addition of  500 µl of  phenol:chloroform (1:1). 
After mixing, debris was removed by centrifuging 
at 13000 rpm for 15 min at 4˚C (Eppendorf  5415R 
refrigerated centrifuge, Eppendorf, Germany). The 
supernatant was transferred to a sterile tube and 
extracted with chloroform: isoamyl alcohol (24:1) by 
centrifuging at 13000 rpm for 15 min. Supernatant 
was transferred to another tube and 50 µl 5M NaCl 
and 1 ml absolute ethanol added. Contents were 
kept overnight on ice to precipitate. Tube content 
was centrifuged, supernatant decanted and pellets 
allowed to dry. Dried pellets were dissolved in 50 µl 
of  sterile water. The DNA extracts were stored at 
-20˚C. 
Primers
Sequences highly conserved in the genus 
Bifidobacterium as designed by Matsuki et al. (1999 
and 2002) using the 16S rRNA sequences were used 
by Biomers (Germany) to synthesize group-specific 
and species-specific gene primers. The specificity 
of  the primers used (Table 1) in this identification 
had been tested and confirmed previously (Matsuki 
et al., 1999; Matsuki et al., 2002). One genus-specific 
gene primer (g-BIFID) and 7 species-specific gene 
primers (B. angulatum BIANG, B. adolescentis BIADO, 
B. bifidum BIBIF, B. breve BIBRE, B. catenulatum 
group BICAT, B. longum BILON and B. dentium 
BIDEN) were applied for molecular identification 
of  the 8 selected isolates. Lyophilized primers were 
dissolved in sterile purified water following the 
manufacturer’s (Biomers, Germany) instructions.
Polymerase Chain Reaction (PCR)
Amplification was carried out based on Matsuki et al. 
(1999 and 2002) method. Each 25 µl PCR mixture 
composed of  10 mM Tris-HCl (pH 8), 50 mM KCl, 
1.5 mM MgCl2, 0.2mM of  each deoxynucleotide 
triphosphate, 0.25µM primer, 2 µl template DNA and 
1U Taq DNA polymerase. Amplification program 
was one cycle of  94˚C for 5 min, 40 cycles of  94˚C 
for 30s, 48˚C for 30s, 72˚C for 1 min, followed by 
one cycle of  72˚C for 5 min using the Eppendorf  
Master Cycler Gradient (Eppendorf, Germany). 
Table 1:  Primers used
 Primer Primer sequence  Reference
Bifidobacterium (group) g-BiFID-F CTCCTGGAAACGGGTGG Matsuki et al., 2002
 g-BiFID-R GGTGTTCTTCCCGATATCTACA 
B. adolescentis BiADO-F CTCCAGTTGGATGCATGTC Matsuki et al., 1999   
 BiADO-R CGAAGGCTTGCTCCCAGT 
B. angulatum BiANG-F CAGTCCATCGCATGGTGGT Matsuki et al., 1999 
 BiANG-R GAAGGCTTGCTCCCCAAC 
B. bifidum BiBIF-F CCACATGATCGCATGTGATTG Matsuki et al., 1999 
 BiBIF-R CCGAAGGCTTGCTCCCAAA 
B. breve BiBRE-F CCGGATGCTCCATCACAC Matsuki et al., 1999 
 BiBRE-R ACAAAGTGCCTTGCTCCCT 
B. catenulatum group BiCAT-F CGGATGCTCCGACTCCT Matsuki et al., 1999 
 BiCAT-R CGAAGGCTTGCTCCCGAT 
B. longum BiLON-F TTCCAGTTGATCGCATGGTC Matsuki et al., 1999 
 BiLON-R GGGAAGCCGTATCTCTACGA 
B. dentium BiDEN-F ATCCCGGGGGTTCGCCT Matsuki et al., 1999 
 BiDEN-R GAAGGGCTTGCTCCCGA
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Electrophoresis
After amplification, the reaction mixtures were 
subjected to 1% (w/v) agarose gel electrophoresis in 
Tris-acetate/EDTA buffer, visualized with ethidium 
bromide/bromophenol blue staining under UV 
light (High Performance UV Transilluminator, 
Upland, USA) and DNA bands captured with 
canon power shot A590 camera. 1Kb DNA ladder 
(O’GeneRuler) was used as marker. 
Antibiotic susceptibility test
The agar overlay disc method was used (Huys et al., 
2002). Isolates were grown anaerobically at 37˚C 
for 24 h in MRS broth supplemented with 0.05% 
cysteine HCl, 1mg/l thymine and 1mg/l riboflavin. 
MRS agar was prepared, poured on plates and 
allowed to solidify. Soft MRS agar (3 ml) cooled 
to about 40˚C was inoculated with 200 µl of  24 h 
broth culture of  isolates and spread on solidified 
MRS agar plates. Soft agar was prepared by adding 
7.5 g/l Oxoid bacteriological agar into MRS broth. 
Inoculated plates were allowed to solidify. Antibiotic 
discs (Abtek Biologicals) were placed on inoculated 
plates which were then incubated at 37˚C for 24 
h in an anaerobic atmosphere. Disc diameter 
was 6 mm. Antibiotics used were cotrimoxazole 
25 µg, chloramhpenicol 10 µg, cloxacillin 5 µg, 
erythromycin 5µg, gentamicin 10 µg, augmentin 
30µg, streptomycin 10 µg, tetracycline 10 µg, 
chloramhpenicol 30 µg and amoxicillin 25 µg. 
Survival of isolates at low temperature in 
yoghurt
Yoghurt was produced using Richard (2001) 
methods with modification. Full cream milk powder 
and granulated sugar were purchased from a Lagos 
market. Two hundred and ten grams (210 g) of  
milk powder and 40 g of  granulated sugar were 
dissolved in 1L sterile distilled water, pasteurized 
at 95˚C for 10 min, cooled to 44˚C and inoculated 
with yoghurt starter culture – S. thermophilus, L. 
bulgaricus and L. acidophilus (Yogomet, Germany). 
Cooled inoculated milk was distributed into 500 ml 
flasks after thorough mixing with magnetic stirrer. 
Flasks and contents were incubated in a water bath 
at 42 – 43˚C and pH monitored until pH dropped 
to 4.5. Produced yoghurt was pasteurized at 85˚C 
for 15 min, refrigerated overnight and divided into 
two. Subsequently, one portion was inoculated 
with test Bifidobacterium isolate culture (HM2, CH3, 
or CH2) as an adjunct to produce the probiotic 
yoghurt. Samples (pasteurized plain yoghurt and 
probiotic yoghurt) were stored in the fridge (4˚C) 
and freezer (-18˚C). The pH, taste and survival of  
isolates were monitored periodically during storage. 
MRS agar supplemented with 0.05% cysteine HCl, 
1mg/l thymine and 1mg/l riboflavin was used for 
survival check. Statistical analysis of  data was done 
using the Duncan Post Hoc tests and descriptive 
statistics.
Results and Discussion
Bifidobacteria obtained from human (5) and 
chicken (3) were anaerobic gram positive non-spore 
forming rods, catalase negative, produced lactic and 
acetic acid without gas from glucose fermentation 
in Oxoid MRS broth. Isolates were phenotypically 
identified to genus level through the production 
of  fructose-6-phosphoketolase enzymes and then 
presumptively identified to species level using their 
carbohydrate fermentation patterns (results not 
shown). Authentication of  identities of  isolates 
at genus and species level was performed by the 
application of  16S rRNA-gene-targeted group and 
species-specific gene primers technique (Tables 1 
and 2). Some PCR-amplified genes are shown in 
Figures 1 and 2. 
Susceptibility of  isolates to some antibiotics is 
reported in Table 3. Three isolates (B. catenulatum 
HM2, B. adolescentis CH2, and B. adolescentis CH3) 
were used to assess ability of  strains to survive low 
storage temperatures (4oC and -18oC). Results are 
as represented in Figure 3 and Figure 4. Strain B. 
catenulatum HM2 and B. adolescentis CH3 did not 
record significant reduction in count up to day 
14 of  storage in yoghurt at 4oC. A decrease of  
about 38.51% and 47.63% occurred at day 30 of  
storage in yoghurt at 4oC for B. catenulatum HM2 
and B. adolescentis CH3 respectively. For strain B. 
Antibiotic Susceptibility Profile and Survival of B. adolescentis and B. catenulatum of Human and Avian Origin ... Onyibe et al.         77
adolescentis CH2 there was no significant reduction 
in number up to day 11 when stored in yoghurt at 
4oC. However, a decrease in number by 38.16% at 
day 14, 68.84% day 22 and 76.86% at day 30 was 
recorded at this storage temperature. When stored 
at -18oC B. catenulatum HM2 exhibited a progressive 
reduction in number from 2.96 x 106 at day 0 to 
1.55 x 106  at day 30.
Table 2: Isolates reaction with group and species-specific primers
Isolate g-BIFID BiADO BiANG BiBIF BiBRE BiCAT gp BiLON BiDEN    Identification
HM1 + - - - - + - - B. catenulatum 
HM2 + - - - - + - - B. catenulatum 
HM3 + - - - - + - - B. catenulatum 
CH1 + + - - - - - - B. adolescentis
HM4 + + - - - - - - B. adolescentis
CH2 + + - - - - - - B. adolescentis
HM5 + - - - - + - - B. catenulatum 
CH3 + + - - - - - - B. adolescentis
Product  (bp) 549-563  279 275 278 288 285 831 387 
+ = positive reaction (amplification), − = no reaction (no amplification)
Table 3: Antibiotic susceptibility of  bifidobacterial isolates (zones in mm)
Strain COT TET STR     AUG GEN ERY CXC CHL1 CHL2 AMX
B. catenulatum HM1 - 12 - 20 8 15 - 18 25 20
B. catenulatum HM2 - 6 - 20 - 20 - 20 30 26
B. catenulatum HM3 - 7 - 20 - 18 - 20 36 25
B. adolescentis HM4  - 18 - 25 - 16 - 20 28 21
B. catenulatum HM5 - 6 - 20 - 20 - 20 30 26
B. adolescentis CH1  - 12 - 25 6 20 6 22 38 15
B. adolescentis CH2  - 18 - 24 - 20 6 20 32 28
B. adolescentis CH3  - 18 - 24 - 20 6 20 32 28
COT = cotrimoxazole 25 µg, CHL1 = chloramphenicol 10 µg, CHL2 = chloramphenicol 30 µg, CXC = cloxacillin 5 µg, 
ERY = erythromycin 5 µg, GEN = gentamicin 10 µg, AUG = augmentin 30 µg, STR = streptomycin 10 µg and TET 
=tetracycline 10 µg, AMX = Amoxycillin 25 µg.
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Though B. adolescentis CH2 maintained its count up 
to day 11, there was a subsequent high reduction on 
day 14 when stored in yoghurt at -186 C. However, 
a reasonable number of  this strain remained until 
day 30 of  storage in yoghurt at this temperature. 
Strain B. adolescentis CH3 decreased by 67.14% 
during storage at -18oC in yoghurt for the 30 days 
investigation period. Despite the foregoing, strains 
maintained high counts after 4 weeks in yoghurt 
stored at the two temperatures (Figure 3 and 
Figure 4). The lowest count after 30 days storage 
in yoghurt was 1.55 x 106 cfu/ml for B. catenulatum 
HM2 at -18oC.  
The specificity of  the primers used in this study 
were previously tested and confirmed by Matsuki 
et al. (1999 and 2002). The results obtained attest 
to their reports. Distinct bands were only obtained 
with the corresponding species primer, indicating 
high specificity, even though 7 different species-
specific gene primers were applied to each isolate. 
The DNA of  the eight isolates whose identity 
were molecularly confirmed, amplified with the 
Bifidobacterium genus gene primer g-BIFID. B. 
catenulatum gp and B. adolescentis, though closely 
related phenotypically, were specifically identified 
molecularly as different species in this study as 
previously documented.
Fig. 2: Agarose gel electrophoresis of  amplified 
genus gene
M = marker (1kb DNA ladder), lane 1 B. adolescentis 
CH2
Fig 1: Agarose gel electrophoresis of  amplified 
Bifidobacterium genus gene 
M  =  marker, LANE 1 B. catenulatum HM1, LANE 
6 B. catenulatum HM2, LANE 7 B. catenulatum 
HM3, LANE 10 B. adolescentis CH1, LANE 13 
B. adolescentis HM4
Fig. 3: Survival of  bifidobacteria in yoghurt at 4oC
CH2 = B. adolecentis CH2, HM2 = B. catenulatum HM2, 
and CH3 = B. adolecentis CH3
Fig 4: Survival of  bifidobacteria in yoghurt at 
-18oC
CH2 = B. adolecentis CH2, HM2 = B. catenulatum HM2, 
and CH3 = B. adolecentis CH3
Values with the same letter (for an isolate) do not 
significantly differ (p > 0.05)
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Isolates susceptibility to nine antibiotics were 
tested. All isolates were resistant to streptomycin. 
This agrees with the result of  Yazid et al. (2000) 
who concluded that bifidobacterial resistance to 
streptomycin appeared to be genus characteristic. 
In this study, resistance to gentamycin appears 
also to be a genus-wide phenomenon. Isolates 
that showed slight susceptibilities (6 mm – 8 mm) 
can be described as resistant as their zones of  
inhibition are very close to the diameter of  the 
disc (6 mm). Masco et al. (2006) and Yazid et al. 
(2000) concluded that all their tested bifidobacteria 
strains were gentamicin-resistant. Other authors 
also reported strain resistance to gentamicin and 
streptomycin (Mättö et al., 2007; Mayrhofer et al., 
2007). Resistance to aminoglycosides in anaerobes 
is seen as natural due to the absence of  cytochrome-
mediated drug transport system which prevents the 
drug from reaching its target (Bryan et al., 1979; 
Bryan and Kwan, 1981). 
All isolates were inhibited by chloramphenicol, 
augmentin and erythromycin. Kheadr et al. (2007), 
Masco et al. (2006) and Yazid et al. (2000) concluded 
that all bifidobacteria tested were susceptible to 
chloramphenicol and erythromycin. This study 
revealed all isolates to be resistant to cotrimoxazole. 
Cotrimoxazole is a combination of  trimethoprim 
and sulphamethoxazole. Masco et al. (2006) 
observed general resistance to sulphamethoxazole 
and variable zones for trimethoprim for tested 
bifidobacteria. But they noted that the strains that 
exhibited susceptibility to trimethoprim showed 
only partial inhibition zones. The resistance of  
studied isolates to cotrimoxazole is therefore in 
agreement with these authors. The sulphonamides 
are said to inhibit cells by interfering with folic acid 
metabolism. They inhibit cells that synthesize their 
own folic acid for growth but will not interfere with 
the growth of  cells which require preformed folic 
acid (Pelczar and Chan, 1981).
Variable zones were observed for tetracycline. 
This was also the conclusion of  Yazid et al. (2000). 
Masco et al. (2006) also recorded that resistance to 
tetracycline was strain specific. Chloramphenicol 
and tetracycline are broad-spectrum antibiotics. 
Atypical tetracycline resistance was exhibited 
by 3 isolates – B. catenulatum HM2, B. catenulatum 
HM3 and B. catenulatum HM5. Other authors have 
also recorded this phenomenon in related studies 
of  bifidobacteria susceptibility to antibiotics 
(Delgado et al., 2008; Lim et al., 1993; Moubareck 
et al., 2005). Further studies by past authors to 
identify the bifidobacteria gene responsible for 
this tetracycline resistance observed the presence 
of  an acquired non-plasmid tet(W) gene which 
was not integrated in the conjugative transposon 
TnB1230 (Florez et al., 2006; Masco et al., 2006). 
Mayrhofer et al. (2011), after primer based PCR 
studies of  antibiotic resistance genes, concluded 
that dominant Bifidobacterium species from human 
intestine frequently harbour acquired tetracycline 
resistance encoded by a tet(W) gene.
In the present study, the eight isolates exhibited 
resistance to cloxacillin. Yazid et al. (2000) reported 
that strains differ in their sensitivity to cloxacillin. 
Kheadr et al. (2007) documented susceptibility 
of  studied bifidobacterial strains to cloxacillin. 
Augmentin (amoxicillin + clavulanic acid) and 
amoxicillin inhibited all isolates in this study. Yazid 
et al. (2000) reported all tested 18 bifidobacteria 
strains from 10 species were sensitive to amoxicillin. 
Masco et al. (2006) concluded a genus susceptibility 
to amoxicillin for Bifidobacterium. Susceptibility to 
these β-lactam antibiotics is expected since there is 
no published report to our knowledge of  detection 
of  β-lactamase activities in Bifidobacterium species 
to date. Authors have reported bacterial resistance 
to β-lactam antibiotics (Kim et al., 1998). Bacterial 
resistance to β-lactam antibiotics (penicillins and 
cephalosporins) is by production of  β-lactamases 
which catalyses the hydrolysis of  the β-lactam ring 
(Bush, 1989; Sanders and Sanders, 1992). Lee and 
Jeong (2002) studied the presence of  phenotypic 
resistance and the genotyping of  β-lactamase in some 
gram negative bacteria and observed occurrence of  
more than one β-lactamase gene in some 45% of  
the isolates. These enzymes confer broad spectrum 
resistance to penicillin and cephalosporin and are 
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said to often be plasmid-mediated (Paterson et al., 
2001). Research for β-lactamase inhibitors led to 
the discovery of  clavulanic acid (Rolinson, 1991). 
Clavulanic acid on its own is a weak antibacterial 
but potent β-lactamase inhibitor and an effective 
potentiator of  antibacterial activity of  penicillins 
and cephalosporins as in augmentin (Buckland 
et al., 1977). With respect to acquired antibiotic 
resistance and probiotic safety, the bifidobacteria 
isolates in this study appear risk-free since only 
few demonstrated atypical resistance to tetracycline 
possibly not based on acquired transmissible gene as 
have been previously reported in past investigations 
(Masco et al., 2006; Moubareck et al., 2005). 
Technological consideration requires that selected 
probiotic organisms be produced, incorporated into 
food products or processed into usable forms and 
stored for variable periods before consumption. 
Previous investigations have documented good 
survival of  species of  Lactobacillus in yoghurt (Onyibe 
et al., 2010) and soymilk (Onyibe et al., 2009) stored 
at low temperatures. Ability of  probiotic agents 
to survive at low temperatures in yoghurt was 
assessed in this study. Incorporated bifodobacteria 
cultures (B. adolescentis CH3, B. catenulatum HM2, B. 
adolescentis CH2) remained viable and were counted 
in adequate amount during storage at 4˚C and 
-18˚C for 4 weeks. 
The good survival of  studied strains in yoghurt at low 
storage temperatures further confirm that probiotic 
bifidobacteria can be packed  and stored in usable 
food forms. Quality and effective probiotics applied 
in these forms are expected to maintain viability 
and impart no negative attributes to such products 
(Heller, 2001; Sarkar, 2008) as was observed in this 
study. The total bacteria, yeast/mould and coliform 
count obtained during quality monitoring of  stored 
yoghurt and probiotic yoghurt in the present study 
collaborated the report of  other researchers that 
probiotic cultures in food products can improve 
the microbiological quality of  foods. No coliform 
was detected, and the bacteria and mould counts 
were lower compared to those obtained in the plain 
yoghurt samples without probiotic cultures (results 
not shown). In their evaluation of  bifidobacteria 
for the production of  antimicrobial compounds 
and assessment of  performance in cottage 
cheese, O’Riordan and Fitzgerald (1998) reported 
significant reduction to no detectable level of  
Pseudomonas in cheese stored at 4˚C on day 14 in the 
presence of  B. longum, B. breve and B. infantis. These 
strains manifested inhibition against Pseudomonas 
in laboratory tests and extended the inhibitory 
activities in stored product even at low temperature, 
supporting the claim that probiotic organisms can 
be applied as preservative and quality control agents 
in manufactured products. 
Conclusion
In addition to presenting acceptable antibiotic 
susceptibility profile and exhibiting good survival 
in stored yoghurt, the bifidobacteria isolates 
evaluated in this study inhibited Staphylococcus aureus 
ATCC 25925 and Escherichia coli ATCC 25922 in-
vitro (results not shown), and demonstrated other 
potential for application as probiotic agents for 
human and agricultural purposes.
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